State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China.
State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Department of Oral and Maxillofacial Surgery, Department of Medical Affairs, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China.
Exp Biol Med (Maywood). 2022 Aug;247(15):1317-1329. doi: 10.1177/15353702221085203. Epub 2022 May 6.
Inhibin subunit βA () is a protein-coding gene belonging to the transforming growth factor β (TGFβ) superfamily, which is associated with the development of a variety of cancers. However, the role of in head and neck squamous cell carcinoma (HNSC) remains unclear. The expression profile and prognostic significance of in HNSC were assessed using a variety of informatics methods. The level of expression was significantly higher in patients with HNSC, and it was correlated with sex, tumor-node-metastasis (TNM) stage, histological grade, and human papillomavirus (HPV) status. Kaplan-Meier (K-M) analysis indicated that poor overall survival (OS) and disease-free survival (DFS) were significantly associated with upregulation in HNSC. overexpression was validated as an independent poor prognostic factor by multivariate Cox regression, and including expression level in the prognostic model could increase prediction accuracy. In addition, copy number alterations (CNAs) of and miR-217-5p downregulation are potential mechanisms for elevated expression in HNSC. In conclusion, may represent a promising predictive biomarker and candidate target for anti-TGFβ therapy in HNSC.
抑制素亚基βA()是转化生长因子β(TGFβ)超家族的一个蛋白编码基因，与多种癌症的发生发展有关。然而，在头颈部鳞状细胞癌（HNSC）中，的作用尚不清楚。本研究采用多种信息学方法评估了在 HNSC 中的表达谱和预后意义。结果发现，HNSC 患者的表达水平显著升高，且与性别、肿瘤-淋巴结-转移（TNM）分期、组织学分级和人乳头瘤病毒（HPV）状态相关。Kaplan-Meier（K-M）分析表明，HNSC 中上调与总生存（OS）和无病生存（DFS）不良显著相关。多因素 Cox 回归验证了过表达是独立的不良预后因素，将表达水平纳入预后模型可以提高预测准确性。此外，和 miR-217-5p 下调的拷贝数改变（CNAs）可能是 HNSC 中上调的潜在机制。综上所述，可能是 HNSC 中一种有前途的预测生物标志物和抗 TGFβ 治疗的候选靶点。
